Focus on what matters

Specialty pharmaceutical company developing unique cannabinoid technologies for treatment of central nervous system disorders.

Our Vision

Specialty pharmaceutical company developing unique cannabinoid technologies for treatment of central nervous system disorders

Meet the People

SciSparc is a specialty clinical-stage pharmaceutical company led by an experienced team of Senior Executives and Scientists. Our focus is creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals.
Come meet the people who help make this possible.

THX-110

A drug candidate platform for the treatment of symptoms related to Tourette syndrome (TS), as well as Obstructive Sleep Apnea (OSA) and chronic pain.

THX-160

An “Ultra Low-Dose” THC targeting the high value and unserved market of Mild Cognitive Impairment (MCI), using a unique and proprietary drug development and delivery dosage platform.

THX-210

A drug candidate intended for the treatment of infectious diseases. It consists of a selected antibacterial agent, with THC or a combination of THC and PEA, to potentially exert antimicrobial synergy.

Cannamide

An innovative and proprietary CB2 receptor agonist formulation intended for the treatment of pain. This specific CB2 receptor agonist was synthesized by Professor Raphael Mechoulam, Ph.D.

Meet Cannamide

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit